Key Record Dates
ClinicalTrials.gov Identifier: | NCT03924856 |
---|---|
Brief Title: | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866) |
First Submitted : | April 22, 2019 |
First Submitted that Met QC Criteria : | April 22, 2019 |
First Posted : | April 23, 2019 |
Last Update Submitted that Met QC Criteria : | January 20, 2023 |
Last Update Posted : | January 23, 2023 |